164 related articles for article (PubMed ID: 28138694)
1. Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion.
Qiu XH; Li F; Cao HQ; Shao JJ; Mei JG; Li HQ; Zhai YP
Mol Med Rep; 2017 Mar; 15(3):1024-1030. PubMed ID: 28138694
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome.
Malli T; Buxhofer-Ausch V; Rammer M; Erdel M; Kranewitter W; Rumpold H; Marschon R; Deutschbauer S; Simonitsch-Klupp I; Valent P; Muellner-Ammer K; Sebesta C; Birkner T; Webersinke G
Genes Chromosomes Cancer; 2016 Jan; 55(1):60-8. PubMed ID: 26391436
[TBL] [Abstract][Full Text] [Related]
3. Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib.
Landberg N; Dreimane A; Rissler M; Billström R; Ågerstam H
Eur J Haematol; 2017 Nov; 99(5):442-448. PubMed ID: 28881484
[TBL] [Abstract][Full Text] [Related]
4. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.
Chase A; Grand FH; Cross NC
Blood; 2007 Nov; 110(10):3729-34. PubMed ID: 17698633
[TBL] [Abstract][Full Text] [Related]
5. Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1.
Yamamoto S; Otsu M; Matsuzaka E; Konishi C; Takagi H; Hanada S; Mochizuki S; Nakauchi H; Imai K; Tsuji K; Ebihara Y
PLoS One; 2015; 10(3):e0120841. PubMed ID: 25803811
[TBL] [Abstract][Full Text] [Related]
6. Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.
Tucker JA; Klein T; Breed J; Breeze AL; Overman R; Phillips C; Norman RA
Structure; 2014 Dec; 22(12):1764-1774. PubMed ID: 25465127
[TBL] [Abstract][Full Text] [Related]
7. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures.
Kähkönen TE; Toriseva M; Petruk N; Virta AR; Maher A; Eigéliené N; Kaivola J; Boström P; Koskivuo I; Nees M; Tuomela JM; Ivaska KK; Härkönen PL
Cell Oncol (Dordr); 2021 Feb; 44(1):205-218. PubMed ID: 33119860
[TBL] [Abstract][Full Text] [Related]
8. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
Ren S; Rivard CJ; Yu H; Genova C; Rozenboom L; Gao D; Hinz TK; Rikke BA; Wynes MW; Caldwell C; Agustoni F; Kenichi Suda ; Jiang T; Zhou C; Heasley LE; Hirsch FR
Clin Lung Cancer; 2018 Sep; 19(5):450-456. PubMed ID: 30146263
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome.
Li F; Zhai YP; Tang YM; Wang LP; Wan PJ
Genes Chromosomes Cancer; 2012 Sep; 51(9):890-7. PubMed ID: 22619110
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
11. Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.
Chase A; Bryant C; Score J; Cross NC
Haematologica; 2013 Jan; 98(1):103-6. PubMed ID: 22875613
[TBL] [Abstract][Full Text] [Related]
12. SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models.
Wu Q; Bhole A; Qin H; Karp J; Malek S; Cowell JK; Ren M
Oncotarget; 2016 Aug; 7(31):49733-49742. PubMed ID: 27391347
[TBL] [Abstract][Full Text] [Related]
13. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1.
Ren M; Hong M; Liu G; Wang H; Patel V; Biddinger P; Silva J; Cowell J; Hao Z
Oncol Rep; 2013 Jun; 29(6):2181-90. PubMed ID: 23563700
[TBL] [Abstract][Full Text] [Related]
14. Molecular identification of a TPR-FGFR1 fusion transcript in an adult with myeloproliferative neoplasm, T-lymphoblastic lymphoma, and a t(1;8)(q25;p11.2).
Kim SY; Kim JE; Park S; Kim HK
Cancer Genet; 2014 Jun; 207(6):258-62. PubMed ID: 25037443
[TBL] [Abstract][Full Text] [Related]
15. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
16. Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1.
Yoza K; Himeno R; Amano S; Kobashigawa Y; Amemiya S; Fukuda N; Kumeta H; Morioka H; Inagaki F
Genes Cells; 2016 Oct; 21(10):1049-1058. PubMed ID: 27558949
[TBL] [Abstract][Full Text] [Related]
17. Effects of FGFR Tyrosine Kinase Inhibition in OLN-93 Oligodendrocytes.
Rajendran R; Böttiger G; Dentzien N; Rajendran V; Sharifi B; Ergün S; Stadelmann C; Karnati S; Berghoff M
Cells; 2021 May; 10(6):. PubMed ID: 34070622
[TBL] [Abstract][Full Text] [Related]
18. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.
Lierman E; Smits S; Cools J; Dewaele B; Debiec-Rychter M; Vandenberghe P
Leukemia; 2012 Jul; 26(7):1693-5. PubMed ID: 22301675
[No Abstract] [Full Text] [Related]
19. The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).
Wasag B; Lierman E; Meeus P; Cools J; Vandenberghe P
Haematologica; 2011 Jun; 96(6):922-6. PubMed ID: 21330321
[TBL] [Abstract][Full Text] [Related]
20. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]